Kornimate/medical-research-clean huggingface dataset:
effect of macadamia nut on cardiometabolic risk factors

Conditions: Cardiovascular Risk Factor; Heart Diseases; Inflammation

Summary: this research study will test the effects of macadamia nuts on adiposity, and traditional and emergent risk factors of cardiometabolic disease in adult men and women

purpose of this study is to investigate the effects of macadamia nuts on body weight, adiposity, , oxidative stress, glucose, insulin an lipid levels. it will a randomized cross over study that will include two study diets (macadamia nut diet and control diet) with a wash out period of 4 weeks in between. 40 subjects will be selected and randomized into either of the two phases. during the macadamia nut diet phase subjects will be provided the appropriate portion of macadamia nuts (15% of daily calories or 30-45 grams based on kcal requirement of the individual, instructions will be provided on how to incorporate nuts into the diet. this phase will last for 8 weeks. during the control diet phase, subjects will continue with their normal diet and abstain from eating nuts. subjects will be tested for various outcomes at baseline and twice at the end of each phase. the intervention will last for 5 months in total.

Eligibility criteria:
inclusion criteria: * healthy men and post-menopausal women * overweight (bmi 25-\<40) * waist circumference ≥88.9 cm for women and ≥101.6 cm for men * at least one of the following within the past year: * plasma triglycerides ≥150mg/dl * blood pressure ≥130/85 mmhg or participants taking antihypertensive medication * fasting glucose ≥100 mg/dl * low density lipoproteins\>= 130 mg/dl exclusion criteria: * nut allergy, any * significant chronic disease including: diabetes, congestive heart failure, renal failure, cirrhosis, or autoimmune disease * medications affecting lipid or glucose metabolism, immune modulators, or antibiotics in the last 6 months * mega-doses of lipid-lowering dietary supplements in the last 6 months * cancer in the last 10 years (with the exception on non-melanoma skin cancer) * pregnancy or lactation * weight change of \>10% of body weight in the last 3 months. * tobacco use * claustrophobia (may affect bod pod testing)

Keywords: macadamia nuts cardiovascular disease inflammation
effect of h. pylori eradication on the reversibility of atrophic gastritis and intestinal metaplasia in korean patients

Conditions: Helicobacter Pylori Infection; Atrophic Gastritis; Intestinal Metaplasia

Summary: helicobacter pylori (h. pylori) infection has been associated with a development of atrophic gastritis and intestinal metaplasia. h. pylori related atrophic gastritis and intestinal metaplasia have been regarded as pre-malignant lesion. however, the role of h. pylori eradication treatment in the reversibility of atrophic gastritis and intestinal metaplasia has not been clearly defined. the aim of the present study was to investigate the relationship between h. pylori eradication and the reversibility of atrophic gastritis and intestinal metaplasia in korean patients.

it is a prospective, case-control study to compare the status of atrophic gastritis and intestinal metaplasia from the patients who undergo h. pylori eradication treatment or not. after enrollment, each patient will be receive annual surveillance upper gastrointestinal endoscopy. the present investigators will monitor the status of atrophic gastritis and intestinal metaplasia annually and finally compare the reversibility of them.

Eligibility criteria:
inclusion criteria: - patients who diagnosis of h. pylori infection * patients presenting with h. pylori related gastrointestinal disease and/or * patients do not have h. pylori related gastrointestinal disease. but, want h. pylori eradication exclusion criteria: - age under 18 years previous eradication treatment for h. pylori patients who took any drug which could influence the study results such as proton pump inhibitor, antibiotics within 4 weeks history of gastrectomy advanced gastric cancer or other malignancy abnormal liver function or liver cirrhosis abnormal renal function or chronic kidney disease other severe concurrent diseases previous allergic reactions to the study drugs pregnant or lactating women

Keywords: helicobacter pylori infection eradication treatment reversibility atrophic gastritis intestinal metaplasia
early access program with arimoclomol in us patients with npc

Conditions: Niemann-Pick Disease, Type C

Summary: npc is a rare, relentlessly progressive, neurological disease and associated with serious morbidity and shortened life expectancy. the purpose of this expanded access program is to provide early access to arimoclomol for patients with niemann-pick type c disease who, in the opinion and the clinical judgement of the treating physician, may benefit from treatment with arimoclomol. participants will receive treatment with arimoclomol until their doctor finds it does not help them anymore, they withdraw, or the study is stopped for any reason.


Eligibility criteria:
inclusion criteria: * the patient has a confirmed diagnosis of npc (npc1 or npc2)\* and at least one neurological symptom. * the patient is two years of age or above. * the patient is a permanent resident of us. * if taking miglustat (zavesca®), the patient must have been on the target dose for the past six weeks. * if the patient is a sexually active female of child-bearing potential (post-menarche), it is agreed to use highly effective contraception during the eap and until three weeks after the last dose of arimoclomol. * confirmed negative urine pregnancy test for sexually active female of child-bearing potential (post-menarche). * all sexually active male patients with female partners of child-bearing potential (postmenarche) agree to use a condom in addition to the birth control used by their partners during treatment and until three weeks after the last dose of arimoclomol. * if the patient has a history of seizures, the condition must be adequately controlled, i.e., the pattern of seizure activity must be stable, and the patient must be on a stable dose and regimen of antiepileptic medication during one month prior to screening. * patient or parent/guardian must provide written informed consent to participate in eap. * in line with patterson et al. 2017 exclusion criteria: * severe liver insufficiency. * renal insufficiency. * the patient has a known or suspected allergy or intolerance to arimoclomol or its constituents. * the patient is pregnant, planning to become pregnant (while on the eap program) or is currently breastfeeding. * the patient will undergo treatment with another investigational drug\*, whilst participating in the program or in the 4 weeks prior to commencing treatment with arimoclomol. * the patient is either eligible and able to participate in or is currently participating in an active interventional clinical trial within the indication. * the patient, in the opinion of the clinician, is unable to comply with the treatment or has a medical condition that would potentially increase the risk to the patient by participation. * the patient has a medical condition which hinders the clinician's assessment of arimoclomol safety and efficacy (e.g. certain epileptic conditions or severe cataplexy). * including unlicensed product provided under an early access program or equivalent compassionate use programs
prevention of delirium in intensive care by melatonin

Conditions: Mechanically Ventilated Patients

Summary: this is a double-blind, randomized, placebo-controlled, phase 2b/3 two-part adaptive clinical trial. the trial is designed to investigate the pharmacokinetics and the efficacy of multiple dosing regimens of melatonin and to confirm the efficacy and safety of one dosing regimen in prevention for delirium.

treatment of the study is a single daily fixed-hour (21h) dose of 15 ml of an oral syrup, at one of the 3 following concentrations of melatonin: 0 mg/ml i.e. 0 mg/day (placebo); 0.02 mg/ml, i.e. 0.3 mg/day (low dose of melatonin) or 0.2 mg/ml, i.e. 3 mg/day (high dose of melatonin). the three dosages will be identical in appearance and volume.treatment will be administered up to day-14 (or death or discharge if these occur before day-14). randomization will be stratified by center.

Eligibility criteria:
inclusion criteria: * age ≥18 years * patient under invasive mechanical ventilation * anticipated stay in intensive care unit of at least 48 hours * informed consent signed by the patient or a relative or emergency consent exclusion criteria: * invasive mechanical ventilation for more than 48 hours * known pregnancy or breastfeeding * no understanding of the french language, deafness * dementia (mini mental state \<20) or known chronic psychosis * delirium (positive cam-icu score) before or at the time of randomization * alcohol withdrawal syndrome before or at the time of randomization with cushman score ≥5 * inability to use the enteral route, food intolerance with vomiting * severe hepatic insufficiency (prothrombin level \<30%) * ongoing treatment with melatonin or a drug that interacts or modifies its metabolism (fluvoxamine, 5- or 8-methoxypsoralen, estrogen, cimetidine, carbamazepine, rifampicin) * known allergy to melatonin * moribund state * patient admitted to intensive care for cardiopulmonary arrest, stroke, head trauma, neurosurgery. * patient not affiliated to social security * patient participating in another interventional clinical study with melatonin and / or for whom delirium is the primary endpoint

Keywords: delirium mechanical ventilation intensive care unit prevention pharmacokinetics melatonin
study of the clinical features of autoimmune hepatitis

Conditions: Hepatitis, Autoimmune

Summary: the purpose of this study is to explore the pathogenes, clinical characteristics, laboratory and histological examination results, treatment and prognosis of autoimmune hepatitis(aih). at phase 1, the investigators focus on studying of the clinical characteristics of acute autoimmune hepatitis, and then will study the difference about treatment effects between acute autoimmune hepatitis and chronic aih. morever, the investigators have noticed that drug induced aih have some special characteristics that may be beneficial to distinguish it with durg induced liver disease. therefore the investigators will do some studies about drug induced aih or other disease which maybe related to the onset of aih.

now this study has been researched at phase 1, the investigators focus on studying the difference between acute aih and chronic aih. in this phase, the investigators analysed the serum biochemical results such as alt,ast,igg,pt,inr and so on, and also compared the histological performance. finally, we compared the percentages of biochemical remission in the two groups, and the time from initial treatment to biochemical remission has also been put into the analysis. now, the investigators are preparing for submitting the manuscript of phase 1.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of autoimmune hepatitis exclusion criteria: * other causes of liver disease, such as viral hepatitis, drug induced liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, overlap syndrome and so on.

Keywords: autoimmune hepatitis, diagnosis, pathogenesis, treatment, prognosis
effect of dexmedetomidine on perioperative internal environment and rehabilitation of patients undergoing gastrointestinal malignant tumor resection

Conditions: Dexmedetomidine; Perioperative; Electrolyte

Summary: dexmedetomidine is a highly selective alpha2-adrenergic receptor agonist with sedative, analgesic, anti-anxiety, and inhibitory sympathetic nerve excitation properties. it is commonly used in clinical anesthesia and intensive care.radical gastrectomy for gastrointestinal malignant tumors is a common major operation in clinical practice, with long operation time, great trauma and strong stress response of patients. dexmedetomidine is often used in general anesthesia during such operations, but its long-term use or large dose may produce certain side effects.common side effects of dexmedetomidine include bradycardia and hypotension, etc. previous studies have reported that dexmedetomidine can prolong qt interval and is at risk of causing tip torsion type ventricular tachycardia.abnormal potassium may affect myocardial repolarization and increase the risk of tip torsion ventricular tachycardia.the main purpose of this study was to observe the effects of long-term use of dexmedetomidine on perioperative internal environment such as electrolyte and rehabilitation indicators during radical general anesthesia for gastrointestinal malignancy, and the secondary purpose was to explore the optimal dose of dexmedetomidine for general anesthesia for patients undergoing radical general anesthesia for gastrointestinal malignancy.


Eligibility criteria:
inclusion criteria: 1. american society of anesthesiologists (asa) physical status i or ii; 2. age between 50-75 years, and a body mass index (bmi) between 18.5-28 kg/m2. exclusion criteria: 1. patients whoused hormones or drugs that have a hypoglycemic nature during the preoperative state, or had bradycardia, arrhythmia, hypotension, abnormal liver or kidney function, pancreatic disease, neuroendocrine malignancy, intraoperative blood transfusion; 2. patients who refused participation and those who needed intensive care after the surgery were also excluded from the study; 3. patients who had severe internal environmental disorders.

Keywords: dexmedetomidine electrolyte haemodynamics rehabilitation internal environment
treat nl (treatment of atopic eczema, the netherlands) registry: dutch national registry for patients with moderate-to-severe atopic eczema on photo- or systemic therapies

Conditions: Moderate-to-severe Atopic Eczema

Summary: the treat nl (treatment of atopic eczema, the netherlands) registry is a national registry for children and adults with moderate-to-severe atopic eczema aiming to gather data on their prescribed photo- and systemic immunomodulating therapies. atopic eczema is a common, chronic, itchy, inflammatory skin disease that can have a major impact on the quality of life of patients and their immediate surroundings. serious atopic eczema patients are treated by means of photo- or systemic immunomodulating therapy. of these mostly off-label applied therapies, there is insufficient evidence on the short and long term for their effectiveness, safety and cost-effectiveness. moreover, good comparative research and real-life data are lacking. with the arrival of new expensive treatments it is crucial to get insight into these treatments in order to improve quality of care. by means of a prospective registry these data can be collected and help to obtain information for clinical practice, for answering research questions, for reducing costs and implementing the results by guidelines and decision aids.


Eligibility criteria:
inclusion criteria: * patient has a diagnosis of atopic eczema, based on the u.k. working party's diagnostic criteria; * starts with any type of phototherapy (e.g. uvb) or systemic immunomodulating therapy (e.g. cyclosporin, systemic glucocorticosteroids, azathioprine, methotrexate, mycophenolic acid, dupilumab); * has voluntarily signed and dated an informed consent prior to any study related procedure or has a legal representative to do so and is willing to comply with the requirements of this study protocol. exclusion criteria: * patient uses only (systemic) antibiotics or antihistamines; * patient starts with systemic immunomodulating therapy for another indication than atopic eczema; * insufficient understanding of the study by the patient or parent/legal representative.

Keywords: atopic eczema atopic dermatitis registries systemic therapies off-label use phototherapy child adult
cognitive behavioral therapy via a smartphone application on bulimia nervosa and binge eating disorder symptoms

Conditions: B.E.D AND BULIMIA PATIENT; SMARTPHONE OWNER; BASIC ENGLISH SPEAKER

Summary: background: research show that cognitive behavioral therapy (cbt) is effective inreducing bulimia nervosa (bn) and binge eating disorder's (bed) symptoms. today, with the development of technology there are efforts being made for developinga treatment to these eating disorders threw the media, most of these attempts are based on the cbt method. the size of the effect that cbt given threw the internet has on bn and bed is still not entirely clear. research presented today are mostly based on treatments that were given threw email or skypeor an automatic self- help stage program. these researches show heterogenic results about the effect it had on eating disorders. in this research we aim to investigate the effect size that a cbt treatment threw a smartphone application that combines a clinician online reply and an automatic feedback in addition to astandard ones a week clinic treatment has on bn and bed symptoms frequency. methods: our aim is to make a research using an application that treats that offers an automatic and human therapist and dietitian reply threw a similar application that is suited for them. a selected 40 bn or sub-threshold bn or bed patients, men and women ages 18-60 ,that will turn to the "sheba eating disorder medical center" will include the research. half of the participants will receive acbt treatment threw a smartphone application along with astandardclinical treatment that includes ones a week session with a therapist and ones a week session with a dietitian and the other half will receive a standardclinic treatment alone. we will test the eating disorder symptoms using eating disorders questionnaires at the starting point, at the end of a six months treatment and six months after finishing the treatment. importance: this research will allow testing the need and benefit that a personal and direct patient- therapist connection has over a standardones a week meeting connection format. in addition, treating with a web application in the future might have a benefit of saving time spent on getting to the clinic, will allow to shorten the time of the session in the clinic and will save cost of the face to face treatment.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of binge eating disorder * clinical diagnosis of bulimia * smrtphone owner * english speaker exclusion criteria: * clinical diagnosis of type 1 diabetes * clinical diagnosis of other axis 1 psychological problems * pregnancy * clinical diagnosis of celiac disease

Keywords: application smartphone bulimia b.e.d binge eating disorder
effect of topical bromelain versus topical corticosteroids in the management of recurrent aphthous stomatitis

Conditions: Recurrent Aphthous Stomatitis

Summary: bromelain, a natural product, exhibits anti-inflammatory, immunomodulatory, and wound-healing properties. however, its efficacy in treating oral mucosal ulcers remains unexplored. this study aims to evaluate the effect of bromelain as a safe alternate for management of ras.


Eligibility criteria:
inclusion criteria: * adults aged 18-60 years. * diagnosed with ras. * onset of ulcer within the last 48 hours. * willingness to participate and provide informed consent. exclusion criteria: * history of hematological deficiencies, git disorders, behcet's disease and major systemic diseases. * pregnant or breastfeeding patients. * previous treatment for the current ulcer episode.
effects of the manual therapy on brain function in young chronic neck pain patients

Conditions: Neck Pain

Summary: the goal of this clinical trial is to study the central remodeling mechanism of young chronic neck pain patients based on resting-state functional magnetic resonance, and also to study the central analgesic mechanism of chinese jingjin manual therapy in treating young chronic neck pain patients. the main question it aims to answer are: are there specific differences in functional brain activities between young chronic neck pain patients and healthy volunteers? are there specific changes in brain network function in young chronic neck pain patients before and after chinese jingjin manual therapy? participants will: the patients in the neck pain group will receive chinese jingjin manual therapy three times a week for five consecutive weeks. before and after the chinese jingjin manual therapy, patients in the neck pain group were assessed by pressure pain threshold, northwick park questionnaire, and hospital anxiety and depression scale. in addition, resting-state functional magnetic resonance data will be collected from the neck pain group and the healthy control group.

chronic neck pain (cnp) is a prevalent condition of the musculoskeletal system that seriously impacts patients' quality of life. the safety and efficacy of chinese jingjin manual therapy, a characteristic of chinese medicine rehabilitation therapy, have been widely recognized. its mechanism of action is believed to be associated with the functional modulation of brain region networks.based on the resting-state functional magnetic resonance imaging (fmri) amplitude of low-frequency fluctuation (alff) technique, to observe the differences in spontaneous activity of brain regions between young cnp patients and healthy people. additionally, the study aims to investigate the changes in brain network function prior to and following the administration of chinese jingjin manual therapy.

Eligibility criteria:
inclusion criteria: compliance with the diagnostic basis of cervical spondylosis in the expert consensus on typology, diagnosis, and nonsurgical treatment of cervical spondylosis issued by china in 2018 and the diagnostic efficacy criteria for chinese medicine issued by state administration of traditional chinese medicine in 2018. neck pain is the main symptom lasting over 12 weeks. between the ages of 18 and 44 and be right-handed. had not received treatment for neck pain within the past month. voluntary participation in the study, ability to complete the entire treatment program, and signing the informed consent form. exclusion criteria: the condition was in the acute phase stage (within two weeks of onset). neck pain is caused by other diseases such as fracture, dislocation, and infection. severe heart, liver, kidney, and other vital organ diseases or cognitive impairment. pregnant or lactating women, severe osteoporosis. metal foreign bodies in the body or other contraindications to fmri examination.